SpectrumX Healthcare Ltd.

LONDON--( BUSINESS WIRE )--SpectrumX, a UK-based healthcare and pharmaceutical company, today announces the appointment of Scott Grant as financial controller. Grant joins SpectrumX’s finance team – led by CFO Barry Saint – at a significant time for the Company, as it grows its commercial offerings and presence across the UK and continental Europe. Grant will manage financial reporting and control activities for SpectrumX. Grant brings top-grade experience in the life sciences sector, focused on financial reporting, risk management and assurance, gained in the industry with a FTSE-100 listed group and as a practitioner at a Big 4 firm. Most recently, he worked as lead finance business partner, and previously as financial controller, at Johnson Matthey, where he worked across the life science and technology business. He was also a senior associate at PwC, with a focus on biotech, for both listed and private entities. He holds a first-class honours degree in accounting and finance from the University of Hertfordshire and he is an ACA Charterholder. Damien Hancox, CEO of SpectrumX, said: “ We are delighted to have Scott join our team. With his sector-specific knowledge and audit background, he will be a key addition as we expand our commercial offerings and prepare for the next stage of our growth.” Barry Saint, CFO of SpectrumX, said : “ Scott joins our growing business at an exciting time in its development. I am pleased to welcome him to the team. He brings a wealth of expertise, and I am certain that he will make a significant contribution to Company’s ongoing success.” - ENDS - For Investors SpectrumX is currently conducting a pre-IPO capital raise in advance of a planned listing on the London Stock Exchange. Interested prospective investors can learn more at https://www.spectrumx.com/investor_relations/ . About SpectrumX SpectrumX is a UK-based healthcare and pharmaceuticals company focused on bringing to market an innovative respiratory infection therapy and the roll-out of the most powerful hand sanitiser in the world to the NHS and other healthcare clients. Both products utilise unique, patent-pending HOCl formulations. HOCl is naturally occurring in human white blood cells and is a key contributor in the immune response to infection. HOCl also has direct killing activity against bacteria, viruses and fungi. It is well-tolerated in humans while also being the most effective known disinfectant when used on surfaces. For more on SpectrumX, visit www.spectrumx.com . For investors, visit https://www.spectrumx.com/investor_relations/ .

LONDON--( BUSINESS WIRE )--SpectrumX, a UK-based healthcare and pharmaceutical company, today announces the appointment of Sheena Powell as regional account manager, UK South West, to its growing sales team. The move comes as CEO Damien Hancox and the SpectrumX team brings its novel Spectricept product line of high-level, skin-safe disinfectants to market and the Company’s plans to expand business further into the UK, Ireland, and Europe. Powell has been brought on board to drive commercial activity and generate growth in the UK’s South West, a market region spanning from the West Midlands down into Dorset, Cornwall, and Hampshire, and also includes South Wales. She is responsible for leading go-to-market and sales strategies in the region, driving product awareness, creating new business opportunities and providing greater support for UK clients. Powell brings a wealth of experience in the healthcare sector to her new role. She holds a master’s degree in infection control from University of the Highlands and Islands, Scotland. She has held progressively senior roles in marketing and sales roles for healthcare and medical supplies companies. Most recently, she was national sales manager for Innovation Rehab, a leading UK manufacturer of orthopaedic and podiatry appliances, and southern regional sales manager for Frontier Medical Group, a leading UK manufacturer and supplier of infection prevention and control products. She also practiced as a registered general nurse at Guy’s and St Thomas’ NHS Hospital Foundation Trust in London, which gives her deep knowledge of infection prevention measures and experience in the healthcare facilities setting. Spectricept products, currently consisting of an alcohol-free hand sanitiser and a body wash, are pH-neutral, high-level disinfectants. The active ingredient is the Company’s patent-pending, stabilised form of hypochlorous acid (HOCl), which lab tests indicate is 99.99% effective against bacteria, viruses, fungi, and yeasts on skin. Damien Hancox said : “This hire comes at a crucial time for us, as we are excited to accelerate our sales programme across the UK for our Spectricept product line. We truly believe we have a game-changer in infection prevention utilising our novel formulation of HOCl, and Sheena will be a key part of the team bringing this to the UK market.” Greg Whelan, director of sales at SpectrumX, said : “Sheena’s 25-plus years of industry experience showcase how deeply embedded she is in the infection prevention community. Her knowledge and understanding of this sector will be an invaluable addition to the SpectrumX team and for our clients. We look forward to her contribution to our continued growth.” Sheena Powell said : “I’m thrilled to join SpectrumX at such a key stage in their business development and showcase the benefits of Spectricept within healthcare settings in the UK. The vision at SpectrumX of aiming to help infection prevention and control clinicians meet some of their current challenges is one to which I am also very committed. I am excited to develop the business and its propositions for the good of customers and patients across the South West.” - ENDS - About SpectrumX SpectrumX is a UK-based healthcare and pharmaceuticals company focused on bringing to market an innovative respiratory infection therapy and the roll-out of the most powerful hand sanitiser in the world to the NHS and other healthcare clients. Both products utilise unique, patent-pending HOCl formulations. HOCl is naturally occurring in human white blood cells and is a key contributor in the immune response to infection. HOCl also has direct killing activity against bacteria, viruses and fungi. It is well-tolerated in humans while also being the most effective known disinfectant when used on surfaces. For more on SpectrumX, visit www.spectrumx.com . For investors, visit https://spectrumx.com/investor-relations/ . Available Media Dropbox Link to photo of Sheena Powell: Click Here